跳转到主要内容
搜索

战略领导力

注册

最新资源

精选资源

Category / type

‘Most Favored Nation’ Policy Could Have Profound Impact on Global Drug Pricing if Fully Implemented
‘Most Favored Nation’ Policy Could Have Profound Impact on Global Drug Pricing if Fully ImplementedBlog

‘Most Favored Nation’ Policy Could Have Profound Impact on Global Drug Pricing if Fully Implemented

Editor’s Note: Jiwon Oh provided research support for this article. She is a Certara Market Access researcher and PharmD/MS in Regulatory Science candidate at…
ILAP 2.0 核心要点全解析
ILAP 2.0 核心要点全解析白皮书

ILAP 2.0 核心要点全解析

This white paper share’s key insights on the relaunch of MHRA’s Innovative Licensing and Access Pathway (ILAP).
Protect Confidential Information in Investigational Drug Submissions
Protect Confidential Information in Investigational Drug SubmissionsBlog

Protect Confidential Information in Investigational Drug Submissions

2025 年 3 月 20 日 Health regulatory agencies require pharmaceutical companies to protect study participants’ personal information (PI) within regulatory drug submissions.…
HIV 病毒学抑制青少年中长效注射用 cabotegravir 与长效注射用 rilpivirine 联合用药的安全性研究（IMPAACT 2017/MOCHA）：一项 1/2 期、多中心、开放标签、非比较性的剂量探索研究
HIV 病毒学抑制青少年中长效注射用 cabotegravir 与长效注射用 rilpivirine 联合用药的安全性研究（IMPAACT 2017/MOCHA）：一项 1/2 期、多中心、开放标签、非比较性的剂量探索研究出版物

HIV 病毒学抑制青少年中长效注射用 cabotegravir 与长效注射用 rilpivirine 联合用药的安全性研究（IMPAACT 2017/MOCHA）：一项 1/2 期、多中心、开放标签、非比较性的剂量探索研究

The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety, antiviral activity, and pharmacokinetics of…

Popular resources

All resources heading

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。


沪ICP备2022021526号
Powered by Translations.com GlobalLink Web Software